Phase 2 N=121 Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
NSAID-induced Gastroduodenal Injury · Ulcers · Rheumatoid Arthritis
Primary: Number of Participants With Gastric Ulcers — 7; 5; 7; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=63 Antioxidant Therapy in RYR1-Related Congenital Myopathy
Neuromuscular Disease
Primary: Urine 15-F2t Isoprostane Concentration — 2.7; 2.6 ng/mg Cr — p=0.88
Phase 2 N=15 A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
ALS
Primary: ALS Functional Rating Scale-revised Version (ALSFRS-R) Slope — -0.39; -0.57 points per month — p=0.32
Phase 2 N=9 Ponatinib in Advanced NSCLC w/ RET Translocations
Non Small Cell Lung Cancer
Primary: Overall Response Rate — 0 Participants
Phase 2 N=63 A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream
Psoriasis Vulgaris
Primary: Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene — 30.2; 30.0 pg/mL
Phase 2 N=61 Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
Type 2 Diabetes
Primary: Mean Change From Baseline in 24-Hour Heart Rate at Days 20 and 48 — -1.86; 6.65; 13.50; 15.80 beats/minute
Phase 2 N=512 Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
Migraine Disorders
Primary: Percentage of Participants With Headache Response — 57.0; 35.8; 49.3; 35.3 percentage of participants — p=<0.0001
Phase 2 N=64 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)
Elevated Lipoprotein(a)
Primary: Percent Change From Baseline in Lipoprotein Lp(a) Plasma Concentration at Day 85/Day 99 — -3.7; -44.5; -70.0; -5.6 percent change — p=<.001
Phase 2 N=224 Phase II Study of Oral Nafithromycin in CABP
Community-Acquired Bacterial Pneumonia (CABP)
Primary: Clinical Response in the ITT Population — 68; 65; 67 Participants
Phase 2 N=120 Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
Hyperlipidemias
Primary: TG Change (mg/dL ) — -9.2; 14.6; -4.2; -1.3 percentage of change
Phase 2 N=16 Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 7; 1 Participants
Phase 2 N=17 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
Tourette Syndrome
Primary: Changes in Tic Severity — 7.6 score on a scale
Phase 2 N=132 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease
Stable Coronary Heart Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 17; 10; 11; 12 Participants
Phase 2 N=162 A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Breast Cancer · Non-small Cell Lung Cancer · Melanoma
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) — 0; 5.8; 0; 0 percentage of participants
Phase 2 N=444 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Microsatellite-instability (MSI) High Colorectal Cancer (CRC) · Endometrial Cancer · Head and Neck Cancer
Primary: Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events — 0; 40.0; 50.0; 45.0 Percentage of…